Literature DB >> 21712260

Feasibility of percutaneous implantation of transapical endocardial left ventricular pacing electrode for cardiac resynchronization therapy.

Imre Kassai1, Orsolya Friedrich, Chandi Ratnatunga, Timothy R Betts, Attila Mihálcz, Tamás Szili-Török.   

Abstract

Failure of coronary sinus lead implantation for resynchronization therapy requires alternative approaches. For such events we have developed a transapical implantation technique as a feasible alternative. We report the outcome of this technique and its evolution from a minithoracotomy to a percutaneous approach. Twenty patients underwent alternative resynchronization therapy with transapical endocardial left ventricular (LV) pacing lead implantation in a multicentre, international study between October 2007 and March 2010. Eighteen patients underwent minithoracotomy and transapical puncture under direct observation. Two recent patients had transthoracic echocardiography-guided percutaneous apical puncture to enter the LV cavity. A 19 or 21 ga needle and two-stage Seldinger dilatation with 4 and 7 Fr sheaths were then used to introduce the lead. In the two patients with closed-chest insertion of the electrode there was no puncture related bleeding or lung damage. Lead dislocation occurred in two minithoracotomy patients. Repositioning was performed without re-opening the pleural cavity. One patient developed right-sided implanted cardiac defibrillator lead endocarditis requiring complete system removal. Twelve patients have >1 year follow-up; all have sustained and significant improvement in LV dimensions (diastolic Δ4.2 ± 2.9, systolic Δ7.2 ± 5.8 mm), ejection fraction (Δ9.5 ± 9.6%), and functional status (Δ1.1 ± 0.3). Transapical placement of LV endocardial pacing lead is an effective alternative strategy for cardiac resynchronization. A closed-chest, percutaneous approach is feasible and should offer even less invasive intervention.

Entities:  

Mesh:

Year:  2011        PMID: 21712260     DOI: 10.1093/europace/eur190

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  6 in total

1.  Right-sided infective endocarditis: recent epidemiologic changes.

Authors:  Shi-Min Yuan
Journal:  Int J Clin Exp Med       Date:  2014-01-15

2.  Long-term cerebral thromboembolic complications of transapical endocardial resynchronization therapy.

Authors:  Zsuzsanna Kis; Andrea Arany; Gabriella Gyori; Attila Mihalcz; Attila Kardos; Csaba Foldesi; Imre Kassai; Tamas Szili-Torok
Journal:  J Interv Card Electrophysiol       Date:  2016-11-12       Impact factor: 1.900

Review 3.  Innovations in Clinical Cardiac Electrophysiology: Challenges and Upcoming Solutions in 2018 and Beyond.

Authors:  Vaibhav R Vaidya; Alan Sugure; Samuel J Asirvatham
Journal:  J Innov Card Rhythm Manag       Date:  2017-12-15

4.  Long-term single-centre large volume experience with transseptal endocardial left ventricular lead implantation.

Authors:  László Gellér; Zoltán Salló; Levente Molnár; Tamás Tahin; Emin Evren Özcan; Valentina Kutyifa; István Osztheimer; Szabolcs Szilágyi; Nándor Szegedi; Pál Ábrahám; Astrid Apor; Klaudia Vivien Nagy; Annamária Kosztin; Dávid Becker; Szilvia Herczeg; Endre Zima; Béla Merkely
Journal:  Europace       Date:  2019-08-01       Impact factor: 5.214

Review 5.  Understanding non-response to cardiac resynchronisation therapy: common problems and potential solutions.

Authors:  Benjamin J Sieniewicz; Justin Gould; Bradley Porter; Baldeep S Sidhu; Thomas Teall; Jessica Webb; Gerarld Carr-White; Christopher A Rinaldi
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

6.  Epicardial left ventricular lead implantation in cardiac resynchronization therapy patients via a video-assisted thoracoscopic technique: Long-term outcome.

Authors:  Massimiliano Marini; Stefano Branzoli; Paolo Moggio; Marta Martin; Giuseppina Belotti; Giulio Molon; Fabrizio Guarracini; Alessio Coser; Silvia Quintarelli; Carlo Pederzolli; Angelo Graffigna; Daniele Penzo; Sergio Valsecchi; Maria Caterina Bottoli; Patrizia Pepi; Roberto Bonmassari; Andrea Droghetti
Journal:  Clin Cardiol       Date:  2019-12-14       Impact factor: 2.882

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.